Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane in Patients With ARDS Secondary to COVID-19
NCT04998253Phase 1Completed
- Sponsor
- Unidad Temporal COVID-19 Centro Citibanamex
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sevoflurane in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Unidad Temporal COVID-19 Centro Citibanamex. Primary endpoints: Evaluation of Oxygenation (PaO2 / FiO2 ratio) at 48 hours and Effect in the hypoxic pulmonary vasoconstriction at 48 hours. Started Oct 2020; status: completed.
02
Drugs
sevoflurane
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04998253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998253.